T 1572/07 (TEM 17/THE JOHNS HOPKINS UNIVERSITY) 29-03-2012

Summary of Facts and Submissions

I. European patent application No. 01961827.1 with the title "Endothelial cell expression patterns" was filed as international application under the Patent Cooperation Treaty with 86 claims. The application was published as WO 02/010217 (referred to in the following as "the application as filed").

II. Claim 11 of the application as filed read as follows:

"11. A method of inhibiting neoangiogenesis, comprising:

administering to a subject in need thereof an effective amount of an isolated molecule comprising an antibody variable region which specifically binds to an extracellular domain of a TEM protein selected from the group consisting of: 1, 9, 17, 19, 22, and 44, as shown in SEQ ID NO: 196, 212, 230, 232, 238, and 271, respectively, whereby neoangiogenesis is inhibited."

III. In a decision posted on 10 April 2007, the examining division of the European Patent Office found that the subject-matter of the claims according to the main request and the second auxiliary request then on file did not meet the requirements of Articles 54 and 56 EPC 1973, and that the amendments introduced into claim 1 according to the first auxiliary request then on file offended against Article 123(2) EPC 1973. Consequently, the examining division decided to refuse the application pursuant to Article 97(1) EPC 1973.

IV. The applicant (appellant) filed an appeal against the decision of the examining division. Together with the statement of grounds of appeal, the appellant submitted three sets of claims as, respectively, main request, first and second auxiliary request. The fresh sets of claims of the main request and first auxiliary request differ from those of the corresponding requests on which the decision under appeal was based, in that claim 26 of each of the present requests is drafted in a "second medical use" format. The claims of the second auxiliary request are identical to those of the corresponding request in examination.

V. Claims 1 and 11 of the main request read as follows:

"1. An isolated molecule comprising an antibody variable region which specifically binds to the protein shown in SEQ ID NO: 230.

11. Use of the isolated molecule according to claim 1 in the manufacture of a medicament for inhibiting neoangiogenesis."

Claims 2 to 10 and claims 12 to 16 are directed to various embodiments of, respectively, the isolated molecule of claim 1 and the use of claim 11. Claim 17 relates to an isolated and purified human transmembrane protein as shown in SEQ ID NO: 230, and claims 18 and 19 to isolated and purified nucleic acid molecules comprising a sequence coding for the transmembrane protein. Claims 20 and 21 concern recombinant host cells. Claims 22, 23 and 33 relate to the use of, respectively, the nucleic acid of claim 18 or 19, the transmembrane protein of claim 17 or a cell expressing the transmembrane protein for inducing an immune response. Independent claims 24, 25 and 32 are directed to various methods for identifying a ligand involved in endothelial cell regulation. Claim 26 relates to the use of a molecule as defined in claim 1 for identifying regions of neoangiogenesis in a patient, and claim 27 to a method of screening for neoangiogenesis in a patient. Finally, independent claims 28 to 31 are directed to various methods for identifying candidate drugs for treating tumours.

VI. Claim 1 of the first auxiliary request reads as follows:

"1. An isolated molecule comprising an antibody variable region which specifically binds to the protein shown in SEQ ID NO: 230, wherein the antibody variable region does not specifically bind to a protein having the following sequence:

FORMULA/TABLE/GRAPHIC

Claims 2 to 33, and in particular claim 11 are identical to the corresponding claims of the main request.

VII. Claim 1 of the second auxiliary request reads as follows:

"1. Use of an isolated molecule comprising an antibody variable region which specifically binds to the protein shown in SEQ ID NO: 230 in the manufacture of a medicament for inhibiting neoangiogenesis."

Claims 2 to 6 and claims 7 to 10 correspond to, respectively, claims 12 to 16 and claims 28 to 31 of the main request.

VIII. The examining division did not rectify the decision to refuse the application. The appeal was remitted to the boards of appeal (Article 109 EPC).

IX. The board summoned the appellant to oral proceedings. In a communication under Rule 15(1) of the Rules of Procedure of the Boards of Appeal (RPBA) attached to the summons, the board, after drawing the appellant's attention to decision G 10/93 of the Enlarged Board of Appeal (OJ EPO 1995, 172), raised fresh objections under Article 123(2) EPC, in particular in respect of claims 11 to 16 of each of the main request and the first auxiliary request (see paragraphs 8 to 10 and 31 of the communication), and in respect of claims 1 to 6 of the second auxiliary request (see paragraph 37 of the communication). Further objections were raised under Articles 84 and 83 EPC. The board also expressed a provisional opinion on some of the findings in the decision under appeal, in particular those concerning the validity of the priority, novelty and inventive step.

X. The appellant did not submit any observations in reply to the communication, but informed the board that it would not attend the oral proceedings. The requests set out in the statement of grounds of appeal were maintained.

XI. At the oral proceedings held on 29 March 2012 the appellant was not represented.

XII. The appellant requested in writing that the decision under appeal be set aside and that a patent be granted on the basis of the claims according to any of the main request, first auxiliary request or second auxiliary request filed together with the statement of grounds of appeal.